<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006928.pub2" GROUP_ID="EYES" ID="083506112410155048" MERGED_FROM="" MODIFIED="2009-04-07 11:38:11 +0200" MODIFIED_BY="Anupa Shah" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-04-07 11:38:11 +0200" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2008-08-07 12:05:20 +0100" MODIFIED_BY="Anupa Shah">Macular translocation for neovascular age-related macular degeneration</TITLE>
<CONTACT MODIFIED="2009-04-07 11:38:11 +0200" MODIFIED_BY="Anupa Shah"><PERSON ID="100FDA6C82E26AA20003EB8A782C55B6" ROLE="AUTHOR"><FIRST_NAME>Chiara</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Eandi</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>chiara.eandi@unito.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Physiopathology, Eye Clinic</DEPARTMENT><ORGANISATION>University of Torino</ORGANISATION><ADDRESS_1>Via Juvarra 19</ADDRESS_1><CITY>Torino</CITY><ZIP>10122</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 011 5666032</PHONE_1><FAX_1>+39 011 539024</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-04-07 11:38:11 +0200" MODIFIED_BY="Anupa Shah"><PERSON ID="100FDA6C82E26AA20003EB8A782C55B6" ROLE="AUTHOR"><FIRST_NAME>Chiara</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Eandi</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>chiara.eandi@unito.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Clinical Physiopathology, Eye Clinic</DEPARTMENT><ORGANISATION>University of Torino</ORGANISATION><ADDRESS_1>Via Juvarra 19</ADDRESS_1><CITY>Torino</CITY><ZIP>10122</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 011 5666032</PHONE_1><FAX_1>+39 011 539024</FAX_1></ADDRESS></PERSON><PERSON ID="193D1E4682E26AA201BA4B5433A0FDB9" ROLE="AUTHOR"><FIRST_NAME>Fabrizio</FIRST_NAME><LAST_NAME>Giansanti</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><EMAIL_1>fabrizio.giansanti@unifi.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neuro-Oto-Ophthalmological Surgical Sciences, Eye Clinic</DEPARTMENT><ORGANISATION>University of Florence</ORGANISATION><ADDRESS_1>Via le Morgagni 85</ADDRESS_1><CITY>Florence</CITY><ZIP>50134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 055 411765</PHONE_1><FAX_1>+39 055 4377749</FAX_1></ADDRESS></PERSON><PERSON ID="11340" ROLE="AUTHOR"><FIRST_NAME>Gianni</FIRST_NAME><LAST_NAME>Virgili</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Associate Professor of Ophthalmology</POSITION><EMAIL_1>gianni.virgili@unifi.it</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neuro-Oto-Ophthalmological Surgical Sciences, Eye Clinic</DEPARTMENT><ORGANISATION>University of Florence</ORGANISATION><ADDRESS_1>Via le Morgagni 85</ADDRESS_1><CITY>Florence</CITY><ZIP>50134</ZIP><COUNTRY CODE="IT">Italy</COUNTRY><PHONE_1>+39 055 411765</PHONE_1><FAX_1>+39 055 4377749</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-04-07 10:36:32 +0100" MODIFIED_BY="Anupa Shah">
<UP_TO_DATE>
<DATE DAY="21" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="21" MONTH="7" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="" MONTH="" YEAR=""/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="10" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-08-07 12:06:34 +0100" MODIFIED_BY="Anupa Shah"/>
<SOURCES_OF_SUPPORT MODIFIED="2008-04-10 16:00:58 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2008-04-10 16:00:58 +0100" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>University of Torino</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2008-04-10 16:00:58 +0100" MODIFIED_BY="[Empty name]">
<NAME>University of Florence</NAME>
<COUNTRY CODE="IT">Italy</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-08-13 23:04:58 +0100" MODIFIED_BY="Anupa Shah">
<SUMMARY MODIFIED="2008-08-08 12:17:12 +0100" MODIFIED_BY="Anupa Shah">
<TITLE MODIFIED="2008-05-20 10:16:41 +0100" MODIFIED_BY="Anupa Shah">Macular translocation for age-related macular degeneration</TITLE>
<SUMMARY_BODY MODIFIED="2008-06-19 15:34:33 +0100" MODIFIED_BY="Anupa Shah" NOTES="&lt;p&gt;Please right click and look at the Handbook Chapter 11 Section 9 for guidance on what to put in a plain language summary.&lt;span modified=&quot;2008-06-19 14:55:00 +0100&quot; modified_by=&quot;Anupa Shah&quot; class=&quot;inserted&quot;&gt; I feel that the summary text needs to be re-arrang&lt;/span&gt;&lt;span modified=&quot;2008-06-19 14:56:00 +0100&quot; modified_by=&quot;Anupa Shah&quot; class=&quot;inserted&quot;&gt;ed so that it fits in with the format suggested by the Handbook.&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-06-19 15:34:33 +0100" NOTES_MODIFIED_BY="Anupa Shah">
<P>It is unclear if macular translocation can improve vision in patients with wet AMD, the form of age-related macular degeneration (AMD) caused by the abnormal growth of new blood vessels in the region of the central retina called macula. Age-related macular degeneration leads to the development of a blind spot in the centre of the visual field and is the most common cause of legal blindness among the elderly in the western world. Macular translocation is a surgical procedure that involves the detachment of the retina which includes the macula into a less-damaged area. Some ophthalmologists have suggested that this surgery can help patients improve vision. We found a small study suggesting that vision might improve, but severe complications can arise during the process of retinal displacement. Thus, macular translocation might not be considered for most patients with wet AMD given the treatment options already available.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-13 23:04:54 +0100" MODIFIED_BY="Anupa Shah">
<ABS_BACKGROUND MODIFIED="2008-08-07 12:18:58 +0100" MODIFIED_BY="Anupa Shah">
<P>Macular translocation has been proposed by vitreoretinal surgeons to displace the neuroretinal tissue onto healthy retinal pigment epithelium and choroid when the macula has been invaded by subretinal neovascularisation.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-05-20 10:13:42 +0100" MODIFIED_BY="Anupa Shah">
<P>This review aims at assessing the effectiveness of macular translocation for preserving or improving vision in patients with neovascular age-related macular degeneration (AMD).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-07 12:27:39 +0100" MODIFIED_BY="Anupa Shah">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>, MEDLINE, EMBASE and Caribbean Literature on Health Sciences (LILACS). There were no language or date restrictions in the search for trials.The electronic databases were last searched on 21 July 2008.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-08-13 23:00:59 +0100" MODIFIED_BY="Anupa Shah">
<P>We included randomised or quasi randomised controlled trials comparing macular translocation with any other treatment or observation.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-04-10 15:19:46 +0100" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted the data. The risk ratio (RR) of visual loss and visual gain was estimated at one year after treatment.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-13 23:04:54 +0100" MODIFIED_BY="Anupa Shah">
<P>Only one small unblinded study on 50 people compared full macular translocation with photodynamic therapy (PDT) in AMD patients with predominantly classic subfoveal choroidal neovascularisation (CNV). At the last examination, performed in most of the cases after one year, there was no difference in the rate of visual loss of 3 or more lines (translocation versus PDT: RR 0.56, 95% confidence interval (CI) 0.22 to 1.43), as well as in the mean change of contrast sensitivity (1 letter favouring translocation; 95% CI -3.51 to 5.51) and the rate of recurrence of CNV (translocation versus PDT: RR 1.56, 95% CI 0.83 to 2.91). Other outcomes significantly favoured translocation, such as the gain of 3 or more ETDRS lines (RR 21, 95% CI 1.30 to 340.02), the mean change of visual acuity (mean difference (MD) 14.60, 95% CI 5.39 to 23.81) and the mean change of near visual acuity score (MD 17.80, 95% CI 3.98 to 31.62) which is obtained with an algorithm. Serious complications reported after macular translocation were retinal detachment in 6/25 patients and diplopia requiring prismatic correction in 5/25 patients.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-06-16 17:01:55 +0100" MODIFIED_BY="[Empty name]">
<P>There is insufficient evidence from randomised controlled trials on the effectiveness of macular translocation, which is also not free of important risks. Furthermore, this technique is difficult to perform and a long surgical training is required. Future studies might include patients with small neovascular lesions that failed to respond to current pharmacological therapies and are willing to accept the risks associated with surgery to try to improve visual acuity.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-08-13 23:04:58 +0100" MODIFIED_BY="Anupa Shah">
<BACKGROUND MODIFIED="2008-08-08 12:43:31 +0100" MODIFIED_BY="Anupa Shah">
<CONDITION MODIFIED="2008-08-08 12:42:05 +0100" MODIFIED_BY="Anupa Shah">
<P>Age-related macular degeneration (AMD) is a progressive and degenerative disease of the retina that occurs with increasing frequency with age. Age-related macular degeneration is the leading cause of legal blindness in people 65 years or older. The number of people affected is projected to increase with the continued aging of the population (<LINK REF="REF-Bunce-2006" TYPE="REFERENCE">Bunce 2006</LINK>; <LINK REF="REF-Friedman-2004" TYPE="REFERENCE">Friedman 2004</LINK>; <LINK REF="REF-Owen-2003" TYPE="REFERENCE">Owen 2003</LINK>). The prevalence of AMD has been estimated to range from 0% among people younger than 55 years to 13% among those 80 years or older (<LINK REF="REF-Friedman-2004" TYPE="REFERENCE">Friedman 2004</LINK>). In the Beaver Dam Eye Study, the 10-year incidence of neovascular AMD was 1.4% in those aged between 43 and 86 years but increased to 4.1% in people over 75 years of age (<LINK REF="REF-Klein-2002" TYPE="REFERENCE">Klein 2002</LINK>). These findings were slightly lower in the Blue Mountain Eye Study (<LINK REF="REF-Mitchell-1995" TYPE="REFERENCE">Mitchell 1995</LINK>).<BR/>There are two major types of AMD: non-neovascular, or atrophic, and neovascular. The non-neovascular type is characterised by drusen (yellow spots under the retina), pigmentary changes (re-distribution of melanin within the retinal pigment epithelial (RPE) cells under the retina and migration of melanin into the retina), and geographic atrophy (loss of the RPE and choriocapillaris). Neovascular AMD is characterised by the presence of choroidal neovascularisation (CNV). While the non-neovascular type is much more common, it is the neovascular type that is responsible for the most severe visual loss (<LINK REF="REF-Leibowitz-1980" TYPE="REFERENCE">Leibowitz 1980</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Presentation and diagnosis</HEADING>
<P>Neovascular AMD usually affects one eye at a time. The symptoms of AMD are metamorphopsia (distortions while looking at objects), scotomata (missing spots) and blurred vision. If AMD affects only one eye, visual loss may go undetected until monocular testing at routine eye examinations or a chance occlusion of the better eye.<BR/>The diagnosis of AMD can be made clinically and with the help of imaging such as angiography. At the onset of symptoms, fundus examination often reveals subretinal exudation of fluid, lipid, or blood. Fluorescein angiography is necessary to detect subtle exudation in some patients with a recent change in vision. Choroidal neovascularisation has several characteristic patterns on fluorescein angiography. Classic CNV is defined as a well-demarcated area with early hyperfluorescence and increasing fluorescein leakage on late frames of the angiogram. Occult CNV occurs in two different patterns: fibrovascular pigment epithelial detachment (PED) and late leakage of an undetermined source.<BR/>Two other imaging tests might be useful to examine patients with neovascular AMD: indocyanine green (ICG) angiography images the choroidal circulation better than fluorescein and may show 'hot' spots under the RPE that are amenable to treatment. Optical coherence tomography (OCT), a non-invasive imaging modality, provides cross-sectional images of the retina, and RPE and choriocapillaries complex. Recent papers define the characteristic appearance of the different stages of the disease process with OCT (<LINK REF="REF-Ting-2002" TYPE="REFERENCE">Ting 2002</LINK>; <LINK REF="REF-Van-Kerckhoven-2001" TYPE="REFERENCE">Van Kerckhoven 2001</LINK>).<BR/>The new vessels originating from the choroid and growing under and through the RPE and Bruch's membrane, may leak and bleed causing exudative or haemorrhagic retinal detachments, or both. The process usually evolves into a fibrous scar, which replaces the outer layers of the retina, the RPE and the choriocapillaris. The scarred retina has a greatly diminished visual function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Treatment options</HEADING>
<P>Treatments for neovascular AMD focus on limiting the growth of new blood vessels within the retina. Original treatments involved application of laser burns to the new vessels (<LINK REF="REF-Virgili-2007" TYPE="REFERENCE">Virgili 2007</LINK>). However regarding the extent of iatrogenic damage to the retina with such laser treatment led to the development of photodynamic therapy (PDT). Photoreactive chemicals are injected into the bloodstream and lower intensity lasers used to activate the chemicals and seal the blood vessels in the retina (<LINK REF="REF-Wormald-2007" TYPE="REFERENCE">Wormald 2007</LINK>). More recent treatments have targeted growth factors within the new vessels. Anti-vascular endothelial growth factors (anti-VEGF) have been shown to be effective in the stabilisation or improvement of visual acuity in people with neovascular AMD and are the subject of a Cochrane review (<LINK REF="REF-Vedula-2008" TYPE="REFERENCE">Vedula 2008</LINK>).<BR/>There are no preventive treatments, however there is some evidence that antioxidant vitamin and mineral supplementation can slow down the progression of the disease in people with moderate AMD (<LINK REF="REF-Evans-2006" TYPE="REFERENCE">Evans 2006</LINK>).<BR/>Surgical management of neovascular AMD has been studied using different techniques. One approach has been removing the CNV by submacular surgery (<LINK REF="REF-de-Juan-1998" TYPE="REFERENCE">de Juan 1998</LINK>). Other surgical treatments for AMD include pneumatic displacement of submacular blood with or without intravitreal or subretinal injection of recombinant tissue plasminogen activator (<LINK REF="REF-Haupert-2001" TYPE="REFERENCE">Haupert 2001</LINK>; <LINK REF="REF-Herriott-1997" TYPE="REFERENCE">Herriott 1997</LINK>; <LINK REF="REF-Ohji-1998" TYPE="REFERENCE">Ohji 1998</LINK>) and translocation of the macula to an extramacular and healthier RPE area (<LINK REF="REF-Machemer-1993a" TYPE="REFERENCE">Machemer 1993a</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2008-08-08 12:43:31 +0100" MODIFIED_BY="Anupa Shah">
<P>Macular translocation is a term used to describe any surgical procedure that involves the deliberate detachment of the retina with subsequent repositioning of the macula to a new location relative to the underlying RPE. It was first developed in animal studies (<LINK REF="REF-Machemer-1993a" TYPE="REFERENCE">Machemer 1993a</LINK>) and subsequently in humans (<LINK REF="REF-Fujii-2002" TYPE="REFERENCE">Fujii 2002</LINK>; <LINK REF="REF-Lambert-2000" TYPE="REFERENCE">Lambert 2000</LINK>; <LINK REF="REF-Machemer-1993b" TYPE="REFERENCE">Machemer 1993b</LINK>; <LINK REF="REF-Vander-2000" TYPE="REFERENCE">Vander 2000</LINK>). The underlying concept for developing this technique is the thought that by moving the fovea away from abnormal pigment epithelium and/or choroid and repositioning it over more normal tissue, macular function can be stabilised or improved (<LINK REF="REF-Au-Eong-2001" TYPE="REFERENCE">Au Eong 2001</LINK>; <LINK REF="REF-de-Juan-2001" TYPE="REFERENCE">de Juan 2001</LINK>; <LINK REF="REF-Vander-2000" TYPE="REFERENCE">Vander 2000</LINK>).<BR/>Macular translocation was first described as a surgery involving the detachment of the entire neurosensory retina with transscleral infusion of fluid beneath the retina, mobilisation of the retina by 360-degree peripheral retinotomy, and rotation of the macula to a new location away from the subretinal neovascular membrane. The retina is then reattached with silicone oil tamponade (<LINK REF="REF-Machemer-1993b" TYPE="REFERENCE">Machemer 1993b</LINK>).<BR/>Other authors reported variations of this surgical technique. Some authors proposed a detachment of the temporal retina only and a 180-degree peripheral retinotomy with a superior or inferior radial incision to move the fovea inferiorly or superiorly, respectively. However, due to the high rate of vitreoretinal proliferation this technique was dismissed (<LINK REF="REF-Ninomiya-1996" TYPE="REFERENCE">Ninomiya 1996</LINK>). Numerous modifications have been applied to the original surgical technique (<LINK REF="REF-Eckardt-1998" TYPE="REFERENCE">Eckardt 1998</LINK>; <LINK REF="REF-Toth-1997" TYPE="REFERENCE">Toth 1997</LINK>; <LINK REF="REF-Wolf-1997" TYPE="REFERENCE">Wolf 1997</LINK>). A limited macular translocation technique was then introduced (<LINK REF="REF-de-Juan-1998" TYPE="REFERENCE">de Juan 1998</LINK>; <LINK REF="REF-Imai-1998" TYPE="REFERENCE">Imai 1998</LINK>; <LINK REF="REF-Seaber-1997" TYPE="REFERENCE">Seaber 1997</LINK>). During this procedure the temporal retina is detached, and with a limbus-parallel arcuate shortening of the choroid and sclera, limited foveal translocation is achieved without an extended peripheral retinotomy.<BR/>Macular translocation surgery is a complex procedure and numerous complications have been reported. The most common intraoperative complications include retinal detachment, retinal breaks, macular holes, macular fold, and intraocular haemorrhage (vitreous, subretinal, or choroidal) (<LINK REF="REF-Fujii-2000" TYPE="REFERENCE">Fujii 2000</LINK>; <LINK REF="REF-Fujii-2001" TYPE="REFERENCE">Fujii 2001</LINK>). The major postoperative complication is retinal detachment with proliferative vitreoretinopathy. Postoperative bleeding, recurrence of subretinal membrane, torsional diplopia, and severe hypotony have been observed (<LINK REF="REF-Eckardt-1999" TYPE="REFERENCE">Eckardt 1999</LINK>; <LINK REF="REF-Fujii-2003" TYPE="REFERENCE">Fujii 2003</LINK>; <LINK REF="REF-Ichibe-2002" TYPE="REFERENCE">Ichibe 2002</LINK>, <LINK REF="REF-Pawlak-2004" TYPE="REFERENCE">Pawlak 2004</LINK>; <LINK REF="REF-Simon-2002" TYPE="REFERENCE">Simon 2002</LINK>; <LINK REF="REF-Trinh-2006" TYPE="REFERENCE">Trinh 2006</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2008-05-20 10:30:03 +0100" MODIFIED_BY="Anupa Shah">
<P>The natural course of the disease leads to the formation of a disciform scar and this unfavourable outcome cannot be avoided in all cases with current treatment options. Therefore, some surgeons suggested that patients not responding to or not eligible for conventional therapies might benefit from macular translocation. Macular translocation has been proposed in those cases with relatively normal RPE near the neovascular lesion. Preliminary results demonstrated the ability of the macula to function in a transposed location using several different surgical techniques. Patients not responding to or not eligible for conventional therapies might benefit from macular translocation surgery.</P>
</THEORY>
<IMPORTANCE MODIFIED="2008-05-20 10:29:54 +0100" MODIFIED_BY="Anupa Shah">
<P>The definitive treatment for neovascular AMD is not established yet. Macular translocation has been used in different cases and with different techniques. A systematic review of this surgical technique will be useful to patients, ophthalmologists and other professionals involved in providing eye health care.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-05-20 10:35:03 +0100" MODIFIED_BY="Anupa Shah">
<P>The primary objective of this review was to examine the effects of macular translocation for CNV associated with AMD. A secondary objective was to compare the effects of different techniques.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-13 23:04:58 +0100" MODIFIED_BY="Anupa Shah">
<SELECTION_CRITERIA MODIFIED="2008-08-13 23:01:39 +0100" MODIFIED_BY="Anupa Shah">
<CRIT_STUDIES MODIFIED="2008-06-19 16:08:48 +0100" MODIFIED_BY="Anupa Shah">
<P>We planned to include randomised controlled trials (RCTs) and quasi-randomised trials in which the methods of allocating people to a trial are not exactly random such as date of birth, day of the week etc. This was in anticipation of not finding many trials on this subject.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-05-20 10:36:02 +0100" MODIFIED_BY="Anupa Shah">
<P>Participants were people affected by CNV associated with AMD.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-13 23:01:39 +0100" MODIFIED_BY="Anupa Shah">
<P>We included any study in which macular translocation was compared to another treatment or no treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-07 13:03:06 +0100" MODIFIED_BY="Anupa Shah">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-05-20 10:36:34 +0100" MODIFIED_BY="Anupa Shah">
<P>The primary outcome for this review was best corrected visual acuity after one year of follow up (plus or minus six months with other time points being secondary outcomes).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-08-07 13:03:06 +0100" MODIFIED_BY="Anupa Shah">
<P>Contrast sensitivity, reading speed or any other validated measures of visual function as available in the studies were secondary outcome measures considered. If sufficient data is found in updates of this review, a meta-analysis will be conducted for contrast sensitivity after one year of follow up (plus or minus six months).</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse outcomes</HEADING>
<P>Any adverse outcomes as reported in trials, particularly retinal detachment and diplopia. Rate of CNV recurrences, either involving the new fovea or not.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Economic data</HEADING>
<P>Comparative cost analysis will be performed if data are available in future updates of this review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life data</HEADING>
<P>If available in future searches, quality of life measures will be extracted from studies reporting on any validated measurement scale, which aims at measuring the impact of visual function loss on quality of life of participants.</P>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-07 13:07:25 +0100" MODIFIED_BY="Anupa Shah">
<ELECTRONIC_SEARCHES MODIFIED="2008-08-07 13:07:00 +0100" MODIFIED_BY="Anupa Shah">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) (<I>The Cochrane Library</I>, Issue 3, 2008), MEDLINE (January 1966 to July 2008), EMBASE (January 1985 to July 2008) and Caribbean Literature on Health Sciences (LILACS) (1982 to July 2008). There were no language or date restrictions in the search for trials. The electronic databases were last searched on 21 July 2008.</P>
<P>See: Appendices for details of search strategies for CENTRAL (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>) and LILACS (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-08-07 13:07:25 +0100" MODIFIED_BY="Anupa Shah">
<P>We handsearched the reference lists of the included trials for other possible trials. References from retrieved articles were also searched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-13 23:04:58 +0100" MODIFIED_BY="Anupa Shah">
<STUDY_SELECTION MODIFIED="2008-08-07 13:07:55 +0100" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently selected the studies for inclusion. The titles and abstracts of all reports identified by the electronic searches and handsearching were examined by the authors. The abstracts were classified as (a) definitely include, (b) unsure and (c) definitely exclude. Full-text copies of those classified as (a) definitely include and (b) unsure were obtained and re-assessed. The studies were classified as (1) included, (2) awaiting assessment and (3) excluded. The authors of studies classified as (2) awaiting assessment will be contacted for further clarification and the studies will be re-assessed as further information becomes available in updates of this review. Studies identified by both review authors as (3) excluded were excluded and documented in the review. Studies identified as (1) included were included and assessed for methodological quality. The review authors were unmasked to the report authors, institutions and trial results during this assessment.</P>
<P>Disagreements between the two review authors were resolved by a third review author.<BR/>
</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-08-13 22:55:47 +0100" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently extracted the data for the primary and secondary outcomes onto paper data extraction forms developed by the Cochrane Eyes and Vision Group. Discrepancies were resolved by discussion. One review author will enter all data into RevMan 5 if further data become available.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-08-13 23:04:58 +0100" MODIFIED_BY="Anupa Shah">
<P>Two review authors independently assessed the included trial for bias according to the methods described in Chapter 8 of the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.0</I> (<LINK REF="REF-Higgins-2008a" TYPE="REFERENCE">Higgins 2008a</LINK>). The protocol was slightly modified according to the updated Handbook as follows:</P>
<OL>
<LI>Sequence generation: the method used to generate the allocation sequence to assess whether it should have produced comparable groups.</LI>
<LI>Allocation concealment: the method used to conceal the allocation sequence to determine whether intervention allocations could have been foreseen in advance of, or during, enrolment.      </LI>
<LI>Masking of personnel and outcome assessors: the assessments were made for each main class of outcomes (i.e. anatomic versus functional outcomes) and considered whether all measures used, if any, to mask study personnel from knowledge of which intervention a participant received were adequate. Masking of participants was not used since this is a complex surgical procedure and it cannot be simulated.</LI>
<LI>Incomplete outcome data: the assessments were made for each main class of outcomes (i.e. anatomic versus functional outcomes), when possible and were based on the description of the completeness of outcome data, including attrition and exclusions from the analysis and their causes, if they were reported.</LI>
<LI>Selective outcome reporting: the possibility of selective outcome reporting, such as found when some measures were obtained, as declared in the methods section or in protocols, but not reported in the results section.</LI>
</OL>
<P>The following grading was used or will be adopted in updates of this review.</P>
<UL>
<LI>Low risk of bias: plausible bias unlikely to seriously alter the results.</LI>
<LI>Unclear risk of bias: plausible bias that raises some doubt about the results</LI>
<LI>High risk of bias: plausible bias that seriously weakens confidence in the results.</LI>
</UL>
<P>If the information available in the published trial reports is inadequate to assess any of the above items of the risk of bias assessment, we will contact the trial authors for clarification. If they do not respond within a reasonable period of time, we will classify the trial based on the available information. When studies do not report any concealment approach, adequacy will be considered unclear. We will also assess the impact of any assumptions made in this regard in a sensitivity analysis.</P>
<P>We considered a trial to have conducted an intention-to-treat analysis only if it includes all participants who were randomised including those randomised but not treated, which were excluded after randomisation for other reasons.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-08-07 13:21:56 +0100" MODIFIED_BY="Anupa Shah">
<P>Data analysis followed guidelines as set out in Chapter 9 of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> <I>5.0.0</I> (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). We will calculate a weighted mean difference for continuous outcomes that become available in future updates. We will do this except if non-normality is suspected, such as when the standard deviation is larger than the mean for a continuous variable which cannot take negative values, such as reading speed. We will calculate a standardised mean difference if different scales are used to measure continuous outcomes. If dichotomous outcomes are summarised we will calculate a summary risk ratio. We will also report the risk difference and number needed to treat.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-08-07 13:22:37 +0100" MODIFIED_BY="Anupa Shah">
<P>The unit of analysis were individual people. Results from paired studies, i.e. studies using the fellow eye as control, will be analysed as recommended following Chapter 16 of the <I>Cochrane Handbook for Systematic Reviews of Interventions 5.0.0 </I>(<LINK REF="REF-Higgins-2008b" TYPE="REFERENCE">Higgins 2008b</LINK>) if they become available. If eyes are the unit of randomisation and a relevant proportion of participants (10% or more) have had both eyes randomised we will consider that there is a significant risk of bias in the variance estimate and possibly the point estimate of the outcome measure. Such studies will be excluded in sensitivity analyses conducted in updates of this review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-08-07 13:58:59 +0100" MODIFIED_BY="Anupa Shah">
<P>Where data are missing due to drop-out of participants in studies retrieved in future searches, we will conduct a primary analysis based on patients with complete data (available case analysis) and a sensitivity analysis with missing imputation if only one of several trials have missing outcomes (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>).<BR/>The assumptions made for imputing will be described if studies are found in updates of this review. Where statistics such as standard deviations or correlation coefficients are missing, the principal investigators will be contacted for details.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-08-07 13:38:56 +0100" MODIFIED_BY="Anupa Shah">
<P>If meta-analyses are conducted in updates of this review, we will look for clinical heterogeneity by examination of the study details then test for statistical heterogeneity between trial results using the chi-square test, and the I-square value (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). We will consider I-square values of more than 50% to be substantial heterogeneity. We will also examine the funnel plot for other sources of heterogeneity if at least 10 studies are found.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-05-20 10:41:31 +0100" MODIFIED_BY="Anupa Shah">
<P>Asymmetry of the funnel plot will be used to identify publication bias if at least 10 studies are found in updates of this review.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-05-20 10:41:19 +0100" MODIFIED_BY="Anupa Shah">
<P>If there is no substantial statistical heterogeneity, and if there is no clinical heterogeneity between the trials, we will combine the results in a meta-analysis using a random-effects model. A fixed-effect model will be used if the number of trials is three or less. In case of substantial statistical or clinical heterogeneity we will not combine study results but present a narrative or tabulated summary.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-08-07 13:24:40 +0100" MODIFIED_BY="Anupa Shah">
<P>Subgroup analyses according to type of surgical technique will be done to investigate for heterogeneity. We will only conduct subgroup analysis if there is a substantial number of trials in the review (three or more in each subgroup).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-05-20 10:41:03 +0100" MODIFIED_BY="Anupa Shah">
<P>Sensitivity analyses will be conducted to determine the impact of exclusion of studies with lower methodological quality, exclusion of unpublished studies, exclusion of quasi-randomised studies and exclusion of industry-funded studies.</P>
<SUBSECTION>
<HEADING LEVEL="5">Methods for future updates </HEADING>
<P>Updates of this review will be conducted every two years after initial publication.</P>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-08-08 13:49:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-08-08 12:42:34 +0100" MODIFIED_BY="Anupa Shah">
<SEARCH_RESULTS MODIFIED="2008-08-08 12:42:34 +0100" MODIFIED_BY="Anupa Shah">
<P>The electronic searches retrieved five references from <I>The Cochrane Library</I>, 69 references from MEDLINE, 80 references from EMBASE and three references from LILACS. After deduplication the search identified a total of 107 references. After independent review of the titles and abstracts by two review authors, four full-text articles were retrieved. Three of these articles referred to one study which was included in the review (<LINK REF="STD-Gelisken-2007" TYPE="STUDY">Gelisken 2007</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-08-08 12:23:51 +0100" MODIFIED_BY="Anupa Shah">
<P>
<LINK REF="STD-Gelisken-2007" TYPE="STUDY">Gelisken 2007</LINK> randomised 50 eyes of 50 patients with predominantly classic subfoveal CNV due to AMD (25 patients per group) comparing visual acuity between two treatment modalities, full macular translocation and PDT. The two groups did not differ in terms of age, gender, arterial hypertension, smoking status, and being phakic.<BR/>Visual outcomes were obtained up to 12 months with intermediate follow up visits at three, six and nine months. These included distance visual acuity with ETDRS charts, contrast sensitivity with Pelli-Robson charts and near visual acuity measured with the Swiss National Association of and for the Blind (SNAB) test cards and converted to near visual acuity scores with the modified Snellen formula, indicating the amount of magnification needed to bring the subject to standard performance. Dichotomous expressions of visual acuity were used. Furthermore, they also reported the mean change of functional measures in the two groups. The use of the mean change may overcome differences in baseline vision between groups and is also less sensitive to deviation from normality of the distribution.<BR/>Anatomic outcomes were evaluated by the presence of leakage on fluorescein angiography. The rate of recurrence was also reported for the two groups.</P>
<P>Study details can be found in the table: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2008-08-07 13:47:28 +0100" MODIFIED_BY="Anupa Shah">
<P>The second study (<LINK REF="STD-Luke-2003" TYPE="STUDY">Luke 2003</LINK>) was excluded from the review because of the design of the study itself. In fact, it was a consecutive case series and no randomisation process was applied. There was no control group with a different treatment modality other than full macular translocation.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-08-08 13:49:57 +0100" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2008-08-08 13:49:57 +0100" MODIFIED_BY="[Empty name]">
<P>In <LINK REF="STD-Gelisken-2007" TYPE="STUDY">Gelisken 2007</LINK> eligible patients were stratified at baseline according to the CNV lesion size and visual acuity, before randomisation. Allocation concealment was obtained using centrally prepared randomisation envelopes, but how the randomisation sequence was obtained and the methods used to conceal the study personnel were not described.</P>
</ALLOCATION>
<BLINDING MODIFIED="2008-08-07 13:48:21 +0100" MODIFIED_BY="Anupa Shah">
<P>Participants as well as the visual acuity examiner and surgeon were not masked, resulting in risk of performance bias and detection bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2008-08-08 13:46:10 +0100" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Gelisken-2007" TYPE="STUDY">Gelisken 2007</LINK> used an intention-to treat analysis. They used the "last observation carried forward" (LOCF) technique to fill in the missing data at 12 months for five patients: one patient deceased in the group assigned to translocation; three did not attend because of illnesses and one refused to attend in the group assigned to PDT. The potential for bias due to missing data should be considered, but the causes of loss to follow-up are well reported and should not be related to treatment accept for the case of the patient who refused to attend the 12-month control. We also suggest that it is unlikely that the higher rate of unattendance among patients treated with PDT due to illness is related to adverse effects of PDT, which is a well tolerated treatment. Therefore, this item is scored as having a low risk of bias.<BR/>We could not conduct sensitivity analyses on missing data using the worst-case/best -case scenarios due to incomplete reporting of the outcomes for the complete cases.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2008-06-12 21:55:37 +0100" MODIFIED_BY="[Empty name]">
<P>All outcomes are reported in detail and there is no suggestion of selective reporting.</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-08 12:17:37 +0100" MODIFIED_BY="Anupa Shah">
<P>
<LINK REF="STD-Gelisken-2007" TYPE="STUDY">Gelisken 2007</LINK> reported that 45/50 (90%) enrolled patients completed the 12-month visit, in particular 24/25 and 21/25 in the macular translocation and PDT groups respectively, and used the LOCF method to fill in missing data, as reported above.</P>
<SUBSECTION>
<HEADING LEVEL="5">Functional outcomes</HEADING>
<P>The authors reported several dichotomous visual acuity measures. The proportion of patients with a loss of 3 or more ETDRS lines did not differ between the two groups (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). The comparisons using the proportion with a gain of 3+ ETDRS lines significantly favoured translocation compared to PDT (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), with a large uncertainty of the estimates due to the fact that no event was recorded among patients treated with PDT, which leads to making assumptions in conventional statistical analyses. Both the mean change of visual acuity and the mean change in near visual acuity score significantly favoured translocation (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). No such significant difference was found for the mean change of contrast sensitivity (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Anatomic outcome</HEADING>
<P>At the 12-month visit, fluorescein angiography revealed CNV recurrence in 14/25 (56%) patients treated with translocation and 9/25 (36%) patients treated with PDT, which is not a statistically significant difference between the two groups (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), although only very large differences can reach statistical significance in such a small study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life outcomes</HEADING>
<P>Several quality of life outcomes as subscales of the National Eye Institute Visual Functioning Questionnaire (NEI-VFQ) were provided (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>; <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>). Although some items favoured macular translocation, a summary score would have been a more reliable outcome measure but was not available in the publication.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse effects</HEADING>
<P>Complications were reported for the two groups, showing minor and less frequent complications in eyes treated with PDT. Macular oedema was present in 11 eyes treated with macular translocation and six required surgery for retinal detachment. In this group muscle surgery was also performed in 23 eyes. Prismatic correction was adopted in five patients complaining of disturbing diplopia after counterrotation.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-07 14:34:44 +0100" MODIFIED_BY="Anupa Shah">
<P>As only one small RCT was found in our systematic review, the effectiveness of full macular translocation for the treatment of subfoveal CNV has not been reliably demonstrated.</P>
<P>The study was a small pilot study which compared macular translocation with PDT in eyes with predominantly classic CNV. The follow-up was of 12 months, the limit considered appropriate in this review. It was not clear if any cut-off of visual acuity was prespecified to define the primary outcome measure. Therefore, we extracted the most commonly used cut-offs, i.e. loss or gain of 3 or more lines, as well as mean visual acuity. A statistically significant difference in favour of macular translocation was found for mean visual acuity and vision improvement, but not for vision worsening, an inconsistency that is not surprising in such a small trial. Considering the high risk of bias associated with a lack of masking and unclear reporting of many quality items, including randomisation technique, allocation concealment and primary outcome definition, the suggestion of benefit found for some but not all expressions of visual acuity, near visual acuity and some subscales of the quality of life questionnaire cannot be considered high-quality evidence in favour of translocation.</P>
<P>Other case series describing the effects of this treatment approach were reported in the literature, but a comparison was not possible due to methodological differences, retrospective design, variable follow-up, variation of the surgical technique, lack of standardised visual acuity examination, different types and sizes of lesions included.</P>
<P>This study presents several limitations, therefore the results should be interpreted with caution. It was a single centre, non-masked study. The largest lesion size was restricted to a four-disc area in order to obtain well-balanced baseline characteristics. Moreover, cataract extraction in phakic eyes together with macular translocation might have resulted in an improvement of visual acuity, at least during the first months of follow-up. Finally, visual and anatomic outcome measures did not consistently suggest a benefit with macular translocation, as the rate of CNV recurrence was high in both groups.</P>
<P>A recent review suggested rates of retinal detachment of 24%, cystoid macular oedema of 44%, recurrent CNV of 56%, and disturbing diplopia of 12% (<LINK REF="STD-Gelisken-2007" TYPE="STUDY">Gelisken 2007</LINK>). Previous case series studies report a recurrence rate of CNV after full macular translocation between 3% and 21% (<LINK REF="REF-Abdel_x002d_Meguid-2003" TYPE="REFERENCE">Abdel-Meguid 2003</LINK>; <LINK REF="REF-Aisenbrey-2002" TYPE="REFERENCE">Aisenbrey 2002</LINK>; <LINK REF="REF-Mruthyunjaya-2004" TYPE="REFERENCE">Mruthyunjaya 2004</LINK>; <LINK REF="REF-Pertile-2002" TYPE="REFERENCE">Pertile 2002</LINK>). The surgeon&#8217;s experience might be an important factor in limiting complications given the difficulty of the technique.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-07 14:17:51 +0100" MODIFIED_BY="Anupa Shah">
<IMPLICATIONS_PRACTICE MODIFIED="2008-04-10 15:46:43 +0100" MODIFIED_BY="[Empty name]">
<P>Little high-quality evidence is available to support the effectiveness of full macular translocation for the treatment of subfoveal CNV due to AMD. Furthermore, the high incidence of CNV recurrence and the severity of complications, as well as the necessity of muscle surgery, should be considered when this treatment modality is proposed to the patient. Moreover, long-term effects on vision are unknown. In the era of pharmacological therapy with anti-VEGF molecules which showed good efficacy, macular translocation should not be offered as first choice therapy for neovascular AMD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-07 14:17:51 +0100" MODIFIED_BY="Anupa Shah">
<P>Larger studies with longer follow-up would be needed to assess the long-term effectiveness of macular translocation for the treatment of CNV in AMD. Given the availability of effective pharmacological therapies, further research might be conducted in patients in which these therapies failed to maintain a useful visual acuity presenting smaller lesions for which the use of translocation has been advocated (<LINK REF="REF-Pawlak-2004" TYPE="REFERENCE">Pawlak 2004</LINK>).</P>
<P>However, it is unlikely that large randomised controlled studies will be conducted given the good anatomical and functional outcomes obtained with these new pharmacological therapies for the treatment of CNV and the limited adverse events reported.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-07 14:19:10 +0100" MODIFIED_BY="Anupa Shah">
<P>We acknowledge the Trials Search Co-ordinator for Cochrane Eyes and Vision Group (CEVG), for devising and running the electronic searches. We thank Anupa Shah, Review Group Co-ordinator for CEVG and the peer referees including Catey Bunce and Francesca Menchini for their assistance and comments, Jennifer Evans for her editorial support. We would also like to thank the following members of the CEVG Consumer Panel for their comments on the abstract and plain language summary of this review: Harold Burton, Bill Crowther, Peter Dyson, Jan Elson, Diana Fitchett, Oliver Keene, Brenda Rogers, Bob Thomas, David Yule.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Chiara Eandi: grants for participation at meetings from Novartis.<BR/>Fabrizio Giansanti: grants for participation at meetings from Allergan, Novartis and Pfizer.<BR/>Gianni Virgili: grants for participation at meetings from Allergan, Novartis and Pfizer; paid participation in advisory boards for Novartis and Pfizer.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-07 14:19:26 +0100" MODIFIED_BY="Anupa Shah">
<P>Conceiving the review: CE, FG, GV<BR/>Designing the review: CE, FG, GV<BR/>Co-ordinating the review: CE<BR/>Data collection for the review<BR/>- Designing electronic search strategies: CEVG editorial base<BR/>- Undertaking manual searches: CE<BR/>- Screening search results: CE, FG<BR/>- Organising retrieval of papers: CE<BR/>- Screening retrieved papers against inclusion criteria: CE, FG, GV<BR/>- Appraising quality of papers: CE, FG, GV<BR/>- Extracting data from papers: CE, FG<BR/>- Writing to authors of papers for additional information: CE<BR/>- Providing additional data about papers: CE<BR/>- Obtaining and screening data on unpublished studies: CE<BR/>-Data management for the review<BR/>- Entering data into RevMan: CE, GV<BR/>Analysis of data: CE, GV<BR/>Interpretation of data<BR/>- Providing a methodological perspective: GV<BR/>- Providing a clinical perspective: CE, FG, GV<BR/>- Providing a policy perspective: CE, FG, GV<BR/>Writing the review: CE, FG, GV<BR/>Providing general advice on the review: GV<BR/>Securing funding for the review: CE<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-08-07 13:16:01 +0100" MODIFIED_BY="Anupa Shah">
<P>Risk of bias table used to judge methodological quality for each study included in the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-07 14:33:17 +0100" MODIFIED_BY="Anupa Shah">
<STUDIES MODIFIED="2008-08-07 14:31:15 +0100" MODIFIED_BY="Anupa Shah">
<INCLUDED_STUDIES MODIFIED="2008-08-07 14:31:15 +0100" MODIFIED_BY="Anupa Shah">
<STUDY DATA_SOURCE="PUB" ID="STD-Gelisken-2007" MODIFIED="2008-08-07 14:31:15 +0100" MODIFIED_BY="Anupa Shah" NAME="Gelisken 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-07 11:33:42 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, et al</AU>
<TI>Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT)</TI>
<SO>Graefe's Archive for Clinical &amp; Experimental Ophthalmology</SO>
<YR>2007</YR>
<VL>245</VL>
<NO>8</NO>
<PG>1085-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-07 11:33:55 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lüke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F</AU>
<TI>Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration--a report of 1 year results</TI>
<SO>Graefe's Archive for Clinical &amp; Experimental Ophthalmology</SO>
<YR>2007</YR>
<VL>245</VL>
<NO>12</NO>
<PG>1831-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-08-07 14:31:15 +0100" MODIFIED_BY="Anupa Shah" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziemssen F, Lüke M, Bartz-Schmidt KU, Gelisken F</AU>
<TI>Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation)</TI>
<SO>Graefes Archive for Clinical and Experimental Ophthalmology</SO>
<YR>2008</YR>
<VL>246</VL>
<NO>5</NO>
<PG>653-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-07 11:27:16 +0100" MODIFIED_BY=" Iris Gordon">
<STUDY DATA_SOURCE="PUB" ID="STD-Luke-2003" MODIFIED="2008-08-07 11:27:16 +0100" MODIFIED_BY=" Iris Gordon" NAME="Luke 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-07 11:27:16 +0100" MODIFIED_BY=" Iris Gordon" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luke C, Alteheld N, Aisenbrey S, Luke M, Bartz-Schmidt KU, Walter P, et al</AU>
<TI>Electro-oculographic findings after 360 degrees retinotomy and macular translocation for subfoveal choroidal neovascularisation in age-related macular degeneration</TI>
<SO>Graefes Archive for Clinical &amp; Experimental Ophthalmology</SO>
<YR>2003</YR>
<VL>241</VL>
<NO>9</NO>
<PG>710-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-07 14:33:17 +0100" MODIFIED_BY="Anupa Shah">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-07 14:33:17 +0100" MODIFIED_BY="Anupa Shah">
<REFERENCE ID="REF-Abdel_x002d_Meguid-2003" MODIFIED="2008-08-07 10:51:05 +0100" MODIFIED_BY=" Iris Gordon" NAME="Abdel-Meguid 2003" TYPE="JOURNAL_ARTICLE">
<AU>Abdel-Meguid A, Lappas A, Hartmann K, Auer F, Schrage N, Thumann G, et al</AU>
<TI>One year follow up of macular translocation with 360 degree retinotomy in patients with age related macular degeneration</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>87</VL>
<NO>5</NO>
<PG>615-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aisenbrey-2002" MODIFIED="2008-08-07 10:53:56 +0100" MODIFIED_BY=" Iris Gordon" NAME="Aisenbrey 2002" TYPE="JOURNAL_ARTICLE">
<AU>Aisenbrey S, Lafaut BA, Szurman P, Grisanti S, Luke C, Krott R, et al</AU>
<TI>Macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2002</YR>
<VL>120</VL>
<NO>4</NO>
<PG>451-9</PG>
<IDENTIFIERS MODIFIED="2008-06-18 06:02:11 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Au-Eong-2001" NAME="Au Eong 2001" TYPE="JOURNAL_ARTICLE">
<AU>Au Eong KG, Fujii GY, Ng EW, Humayun MS, Pieramici DJ, de Juan E Jr</AU>
<TI>Transient formed visual hallucinations following macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2001 May</YR>
<VL>131</VL>
<NO>5</NO>
<PG>664-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunce-2006" NAME="Bunce 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bunce C, Wormald R</AU>
<TI>Leading causes of certification for blindness and partial sight in England &amp; Wales</TI>
<SO>BMC Public Health</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Juan-1998" NAME="de Juan 1998" TYPE="JOURNAL_ARTICLE">
<AU>de Juan E Jr, Loewenstein A, Bressler NM, Alexander J</AU>
<TI>Translocation of the retina for management of subfoveal choroidal neovascularization II: a preliminary report in humans</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1998 May</YR>
<VL>125</VL>
<NO>5</NO>
<PG>635-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-de-Juan-2001" NAME="de Juan 2001" TYPE="JOURNAL_ARTICLE">
<AU>de Juan E Jr, Fujii GY</AU>
<TI>Limited macular translocation</TI>
<SO>Eye</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>Pt 3</NO>
<PG>413-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2008-06-19 15:50:15 +0100" MODIFIED_BY="Anupa Shah" NAME="Deeks 2008" TYPE="OTHER">
<AU>Deeks JJ, Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eckardt-1998" NAME="Eckardt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Eckardt U, Eckardt C</AU>
<TI>Orthoptic problems after macular rotation with and without muscle surgery</TI>
<SO>Klinische Monatsblatter fur Augenheilkunde</SO>
<YR>1998</YR>
<VL>212</VL>
<NO>4</NO>
<PG>212-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eckardt-1999" NAME="Eckardt 1999" TYPE="JOURNAL_ARTICLE">
<AU>Eckardt C, Eckardt U, Conrad HG</AU>
<TI>Macular rotation with and without counter-rotation of the globe in patients with age-related macular degeneration</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1999</YR>
<VL>237</VL>
<NO>4</NO>
<PG>313-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-2006" NAME="Evans 2006" TYPE="COCHRANE_REVIEW">
<AU>Evans JR</AU>
<TI>Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Friedman-2004" NAME="Friedman 2004" TYPE="JOURNAL_ARTICLE">
<AU>Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, et al</AU>
<TI>Prevalence of age-related macular degeneration in the United States</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2004</YR>
<VL>122</VL>
<NO>4</NO>
<PG>564-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujii-2000" NAME="Fujii 2000" TYPE="JOURNAL_ARTICLE">
<AU>Fujii GY, Pieramici DJ, Humayun MS, Schachat AP, Reynolds SM, Melia M, et al</AU>
<TI>Complications associated with limited macular translocation</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2000</YR>
<VL>130</VL>
<NO>6</NO>
<PG>751-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujii-2001" NAME="Fujii 2001" TYPE="JOURNAL_ARTICLE">
<AU>Fujii GY, Humayun MS, Pieramici DJ, Schachat AP, Au Eong KG, de Juan E Jr</AU>
<TI>Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2001</YR>
<VL>131</VL>
<NO>1</NO>
<PG>90-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujii-2002" NAME="Fujii 2002" TYPE="JOURNAL_ARTICLE">
<AU>Fujii GY, Au Eong KG, Humayun MS, de Juan E Jr</AU>
<TI>Limited macular translocation: current concepts</TI>
<SO>Ophthalmology Clinics of North America</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>425-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fujii-2003" NAME="Fujii 2003" TYPE="JOURNAL_ARTICLE">
<AU>Fujii GY, de Juan E Jr, Humayun MS, Chang TS</AU>
<TI>Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>135</VL>
<NO>1</NO>
<PG>109-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glanville-2006" NAME="Glanville 2006" TYPE="JOURNAL_ARTICLE">
<AU>Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J</AU>
<TI>How to identify randomized controlled trials in MEDLINE: ten years on</TI>
<SO>Journal of the Medical Library Association</SO>
<YR>2006</YR>
<VL>94</VL>
<NO>2</NO>
<PG>130-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haupert-2001" NAME="Haupert 2001" TYPE="JOURNAL_ARTICLE">
<AU>Haupert CL, McCuen BW 2nd, Jaffe GJ, Steuer ER, Cox TA, Toth CA, et al</AU>
<TI>Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2001</YR>
<VL>131</VL>
<NO>2</NO>
<PG>208-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herriott-1997" MODIFIED="2008-08-07 11:43:32 +0100" MODIFIED_BY=" Iris Gordon" NAME="Herriott 1997" TYPE="CONFERENCE_PROC">
<AU>Herriot WJ</AU>
<SO>Further experience in management of submacular hemorrhage with intravitreal t-PA. Proceeding of 1997 update on macular surgery; 1997 Oct 26-29 ; San Francisco</SO>
<YR>1997</YR>
<PG>82-4</PG>
<PB>American Academy Ophthalmology</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008a" MODIFIED="2008-06-19 15:37:54 +0100" MODIFIED_BY="Anupa Shah" NAME="Higgins 2008a" TYPE="OTHER">
<AU>Higgins JPT, Altman DG (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008b" MODIFIED="2008-06-19 15:41:05 +0100" MODIFIED_BY="Anupa Shah" NAME="Higgins 2008b" TYPE="OTHER">
<AU>Higgins JPT, Deeks JJ, Altman DG (editors)</AU>
<TI>Chapter 16: Special topics in statistics</TI>
<SO>In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 (updated February 2008). The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ichibe-2002" NAME="Ichibe 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ichibe M, Yoshizawa T, Funaki S, Funaki H, Ozawa Y, Tanaka Y, et al</AU>
<TI>Severe hypotony after macular translocation surgery with 360-degree retinotomy</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2002</YR>
<VL>134</VL>
<NO>1</NO>
<PG>139-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Imai-1998" NAME="Imai 1998" TYPE="JOURNAL_ARTICLE">
<AU>Imai K, Lowenstein A, de Juan E</AU>
<TI>Translocation of the retina for management of subfoveal choroidal neovascularisation I: Experimental studies in the rabbit eye</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1998</YR>
<VL>125</VL>
<NO>5</NO>
<PG>627-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klein-2002" NAME="Klein 2002" TYPE="JOURNAL_ARTICLE">
<AU>Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH</AU>
<TI>Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study</TI>
<SO>Ophthalmology</SO>
<YR>2002</YR>
<VL>109</VL>
<NO>10</NO>
<PG>1767-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lambert-2000" NAME="Lambert 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lambert HM</AU>
<TI>The management of subfoveal choroidal neovascular membranes and hemorrhage</TI>
<SO>Seminars in Ophthalmology</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>2</NO>
<PG>92-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leibowitz-1980" NAME="Leibowitz 1980" TYPE="JOURNAL_ARTICLE">
<AU>Leibowitz HM, Krueger DE, Maunder LR, Milton RC, Kini MM, Kahn HA, et al</AU>
<TI>The Framingham Eye Study monograph: An ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975</TI>
<SO>Survey of Ophthalmology</SO>
<YR>1980</YR>
<VL>24</VL>
<NO>Suppl</NO>
<PG>335-610</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Machemer-1993a" NAME="Machemer 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Machemer R, Steinhorst UH</AU>
<TI>Retinal separation, retinotomy, and macular relocation: I. Experimental studies in the rabbit eye</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1993</YR>
<VL>231</VL>
<NO>11</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Machemer-1993b" NAME="Machemer 1993b" TYPE="JOURNAL_ARTICLE">
<AU>Machemer R, Steinhorst UH</AU>
<TI>Retinal separation, retinotomy, and macular relocation: II. A surgical approach for age-related macular degeneration?</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1993</YR>
<VL>231</VL>
<NO>11</NO>
<PG>635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mitchell-1995" NAME="Mitchell 1995" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell P, Smith W, Attebo K, Wang JJ</AU>
<TI>Prevalence of age-related maculopathy in Australia. The Blue Mountains Eye Study</TI>
<SO>Ophthalmology</SO>
<YR>1995</YR>
<VL>102</VL>
<NO>10</NO>
<PG>1450-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mruthyunjaya-2004" MODIFIED="2008-08-07 10:59:13 +0100" MODIFIED_BY=" Iris Gordon" NAME="Mruthyunjaya 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mruthyunjaya P, Stinnett SS, Toth CA</AU>
<TI>Change in visual function after macular translocation with 360° retinectomy for neovascular age-related macular degeneration</TI>
<SO>Ophthalmology</SO>
<YR>2004</YR>
<VL>111</VL>
<NO>9</NO>
<PG>1715-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ninomiya-1996" NAME="Ninomiya 1996" TYPE="JOURNAL_ARTICLE">
<AU>Ninomiya Y, Lewis JM, Hasegawa T, Tano Y</AU>
<TI>Retinotomy and foveal translocation for surgical management of subfoveal choroidal neovascular membranes</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>1996</YR>
<VL>122</VL>
<NO>5</NO>
<PG>613-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohji-1998" NAME="Ohji 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ohji M. Saito Y. Hayashi A. Lewis JM. Tano Y</AU>
<TI>Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator</TI>
<SO>Archives of Ophthalmology</SO>
<YR>1998</YR>
<VL>116</VL>
<NO>10</NO>
<PG>1326-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Owen-2003" NAME="Owen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Owen CG, Fletcher AE, Donoghue M, Rudnicka AR</AU>
<TI>How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?</TI>
<SO>British Journal of Ophthalmology</SO>
<YR>2003</YR>
<VL>87</VL>
<NO>3</NO>
<PG>312-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pawlak-2004" MODIFIED="2008-08-07 14:33:17 +0100" MODIFIED_BY="Anupa Shah" NAME="Pawlak 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pawlak D, Glacet-Bernard A, Papp M, Coscas G, Soubrane G</AU>
<TI>Results of limited macular translocation in subfoveal choroidal neovascularization in age-related macular degeneration</TI>
<SO>Journal Francais d' Opthalmologie</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>9 Pt 2</NO>
<PG>3S31-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pertile-2002" MODIFIED="2008-08-07 11:01:50 +0100" MODIFIED_BY=" Iris Gordon" NAME="Pertile 2002" TYPE="JOURNAL_ARTICLE">
<AU>Pertile G, Claes C</AU>
<TI>Macular translocation with 360 degree retinotomy for management of age-related macular degeneration with subfoveal choroidal neovascularization</TI>
<SO>American Journal of Ophthalmology</SO>
<YR>2002</YR>
<VL>134</VL>
<NO>4</NO>
<PG>560-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seaber-1997" NAME="Seaber 1997" TYPE="JOURNAL_ARTICLE">
<AU>Seaber JH, Machemer R</AU>
<TI>Adaptation to monocular torsion after macular translocation</TI>
<SO>Graefe's Archive for Clinical and Experimental Ophthalmology</SO>
<YR>1997</YR>
<VL>235</VL>
<NO>2</NO>
<PG>76-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simon-2002" NAME="Simon 2002" TYPE="JOURNAL_ARTICLE">
<AU>Simon P, Glacet-Bernard A, Coscas G, Soubrane G</AU>
<TI>Progression of choroidal neovascularization after macular translocation in age-related macular degeneration and degenerative myopia</TI>
<SO>Journal Francais d' Opthalmologie</SO>
<YR>2002</YR>
<VL>25</VL>
<NO>7</NO>
<PG>694-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ting-2002" NAME="Ting 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ting TD, Oh M, Cox TA, Meyer CH, Toth CA</AU>
<TI>Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration</TI>
<SO>Archives of Ophthalmology</SO>
<YR>2002</YR>
<VL>120</VL>
<NO>6</NO>
<PG>731-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toth-1997" NAME="Toth 1997" TYPE="CONFERENCE_PROC">
<AU>Toth C, Machemer R</AU>
<SO>Macular translocation: techniques and results. Vitreoretinal update. American Academy of Ophthalmology Subspecialty Day 1997 Oct 26-29 ; San Francisco</SO>
<YR>1997</YR>
<PB>American Accademy of Ophthalmology</PB>
<CY>San Francisco</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trinh-2006" NAME="Trinh 2006" TYPE="JOURNAL_ARTICLE">
<AU>Trinh L, Glacet-Bernard A, Colasse-Marthelot V, Leynaud JL, Soubrane G</AU>
<TI>Macular fold following retinal detachment surgery</TI>
<SO>Journal Francais d' Opthalmologie</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>9</NO>
<PG>995-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Kerckhoven-2001" NAME="Van Kerckhoven 2001" TYPE="JOURNAL_ARTICLE">
<AU>Van Kerckhoven W, Lafaut B, Follens I, De Laey JJ</AU>
<TI>Features of age-related macular degeneration on optical coherence tomography</TI>
<SO>Bulletin De La Societe Belge d' Ophtalmologie</SO>
<YR>2001</YR>
<VL>281</VL>
<PG>75-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vander-2000" NAME="Vander 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vander JF</AU>
<TI>Macular translocation</TI>
<SO>Current Opinion in Ophthalmology</SO>
<YR>2000</YR>
<VL>11</VL>
<NO>3</NO>
<PG>159-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vedula-2008" MODIFIED="2008-08-07 12:48:33 +0100" MODIFIED_BY="Anupa Shah" NAME="Vedula 2008" TYPE="COCHRANE_REVIEW">
<AU>Vedula SS, Krzystolik MG</AU>
<TI>Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-08-07 12:48:33 +0100" MODIFIED_BY="Anupa Shah">
<IDENTIFIER MODIFIED="2008-08-07 12:48:33 +0100" MODIFIED_BY="Anupa Shah" TYPE="DOI" VALUE="10.1002/14651858.CD005139.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Virgili-2007" NAME="Virgili 2007" TYPE="COCHRANE_REVIEW">
<AU>Virgili G, Bini A</AU>
<TI>Laser photocoagulation for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD004763. DOI: 10.1002/14651858.CD004763.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wolf-1997" NAME="Wolf 1997" TYPE="JOURNAL_ARTICLE">
<AU>Wolf S</AU>
<TI>Early experience with macular translocation as treatment of subfoveal choroidal neovascularisation</TI>
<SO>Klinische Monatsblatter fur Augenheilkunde</SO>
<YR>1997</YR>
<VL>210</VL>
<NO>Suppl</NO>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wormald-2007" NAME="Wormald 2007" TYPE="COCHRANE_REVIEW">
<AU>Wormald R, Evans J, Smeeth L, Henshaw K</AU>
<TI>Photodynamic therapy for neovascular age-related macular degeneration</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="Art. No.: CD002030. DOI: 10.1002/14651858.CD002030.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-13 23:18:21 +0100" MODIFIED_BY="Anupa Shah">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-13 23:18:21 +0100" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-13 23:18:21 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Gelisken-2007">
<CHAR_METHODS MODIFIED="2008-08-07 14:21:11 +0100" MODIFIED_BY="Anupa Shah">
<P>Eligible patients were stratified by baseline according to the CNV lesion size, visual acuity and randomised thereafter. An independent unit performed the stratification and prepared the randomisation envelopes, but no other details on allocation concealment are given.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-08 12:38:43 +0100" MODIFIED_BY="Anupa Shah">
<P>Setting: Tuebingen, Germany<BR/>Age range: 65 to 71 years (full macular translocation group); 65 to 87 years (PDT group)<BR/>Sex:<BR/>Full macular translocation group - 11 (44%) female; 14 (56%) male<BR/>PDT group - 16 (64%) female; 9 (36%) male<BR/>50 eyes of 50 patients with predominantly classic subfoveal CNV due to AMD; patients with prior treatments for exudative AMD were excluded.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-07 14:21:13 +0100" MODIFIED_BY="Anupa Shah">
<P>Full macular translocation versus PDT.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-13 23:18:21 +0100" MODIFIED_BY="Anupa Shah">
<P>Functional: visual acuity, contrast sensitivity, near acuity.</P>
<P>Anatomic: recurrence of CNV.</P>
<P>Quality of life assessed with the NEI-VFQ 25 questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AMD: age-related macular degeneration<BR/>CNV: choroidal neovascularisation<BR/>FU: follow up<BR/>LOCF: last observation carried forward<BR/>PDT: photodynamic therapy</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-08-07 14:25:44 +0100" MODIFIED_BY="Anupa Shah" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2008-08-07 14:25:44 +0100" MODIFIED_BY="Anupa Shah" STUDY_ID="STD-Luke-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-07 14:25:44 +0100" MODIFIED_BY="Anupa Shah">
<P>Not a randomised study (consecutive case series).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-08 13:45:45 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-08-08 13:45:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-08 13:45:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gelisken-2007">
<DESCRIPTION>
<P>Centrally prepared randomisation envelopes by the Department of Medical Biometry but method not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-08 13:45:45 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-08 13:45:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gelisken-2007">
<DESCRIPTION>
<P>Randomisation performed after patients were deemed eligible, but methods used to conceal study personnel not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-08-07 14:23:51 +0100" MODIFIED_BY="Anupa Shah" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 14:23:51 +0100" MODIFIED_BY="Anupa Shah" RESULT="NO" STUDY_ID="STD-Gelisken-2007">
<DESCRIPTION>
<P>Unmasked study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-08-07 14:24:53 +0100" MODIFIED_BY="Anupa Shah" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-07 14:24:53 +0100" MODIFIED_BY="Anupa Shah" RESULT="YES" STUDY_ID="STD-Gelisken-2007">
<DESCRIPTION>
<P>Five did not reach the 12 month examination; reasons for loss to FU were probably not related to outcomes (illness or death), however, the LOCF method was used to take into account missing values.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-08-06 17:43:55 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-06 17:43:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gelisken-2007">
<DESCRIPTION>
<P>Critical outcomes are reported in detail and visual acuity data could be extracted for the more commonly used cut-offs (gain or loss of 3 or more lines), however, the primary outcome was not specified in the methods section.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-05-13 13:25:58 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-04-10 16:14:45 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-13 23:04:28 +0100" MODIFIED_BY="Anupa Shah">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-13 23:04:28 +0100" MODIFIED_BY="Anupa Shah" NO="1">
<NAME>Macular translocation versus photodynamic therapy</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-16 16:47:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Loss of 3+ ETDRS lines at 12 months</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours translocation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.425391844248244" CI_START="0.2165313184259313" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.15393426953872594" LOG_CI_START="-0.664479279745338" LOG_EFFECT_SIZE="-0.255272505103306" MODIFIED="2008-06-12 17:35:53 +0100" MODIFIED_BY="[Empty name]" ORDER="2" O_E="0.0" SE="0.48074017006186526" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.23111111111111113" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-16 16:43:17 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>Gain of 3+ ETDRS lines at 12 months</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<DICH_DATA CI_END="340.01597105640445" CI_START="1.2969978987453021" EFFECT_SIZE="21.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="2.531499316979795" LOG_CI_START="0.1129392724880434" LOG_EFFECT_SIZE="1.3222192947339193" MODIFIED="2008-04-10 16:09:05 +0100" MODIFIED_BY="[Empty name]" ORDER="3" O_E="0.0" SE="1.4206741421997582" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" VAR="2.0183150183150187" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2008-06-16 16:44:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="30.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="letters" WEIGHT="0.0" Z="0.0">
<NAME>Mean change of visual acuity at 12 months</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.81391555948611" CI_START="5.386084440513894" EFFECT_SIZE="14.600000000000001" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="-11.9" MODIFIED="2008-06-12 17:14:41 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="18.5" SD_2="14.5" SE="4.701063709417263" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2008-06-16 16:44:45 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="15.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="letters" WEIGHT="0.0" Z="0.0">
<NAME>Mean change of contrast sensitivity at 12 months</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.508982236439135" CI_START="-3.5089822364391354" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="-2.0" MEAN_2="-3.0" MODIFIED="2008-06-12 17:32:50 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SD_1="8.5" SD_2="7.75" SE="2.3005434140654684" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-06-16 16:45:00 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Mean change of near visual acuity scores at 12 months</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="31.616008425022443" CI_START="3.9839915749775585" EFFECT_SIZE="17.8" ESTIMABLE="YES" MEAN_1="7.4" MEAN_2="-10.4" MODIFIED="2008-06-12 17:33:31 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="30.0" SD_2="18.5" SE="7.049113419430843" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="14" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2008-06-16 16:45:31 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>CNV recurrence at 12 months</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours translocation</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PDT</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9137731355635283" CI_START="0.830453495807857" EFFECT_SIZE="1.5555555555555556" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="9" LOG_CI_END="0.4644557348710394" LOG_CI_START="-0.08068468239321319" LOG_EFFECT_SIZE="0.19188552623891314" MODIFIED="2008-04-10 16:09:58 +0100" MODIFIED_BY="[Empty name]" ORDER="4" O_E="0.0" SE="0.32021817958960813" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" VAR="0.10253968253968251" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-06-16 16:45:55 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: General Health (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.405480089864636" CI_START="-12.605480089864635" EFFECT_SIZE="-2.1" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="6.0" MODIFIED="2008-06-12 15:23:01 +0100" MODIFIED_BY="[Empty name]" ORDER="5" SD_1="16.0" SD_2="21.5" SE="5.360037313302959" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-06-16 16:46:02 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Distance Activity (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.194046786615893" CI_START="-0.3940467866158901" EFFECT_SIZE="10.4" ESTIMABLE="YES" MEAN_1="10.9" MEAN_2="0.5" ORDER="15" SD_1="24.0" SD_2="13.5" SE="5.5072679252057455" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-06-16 16:46:08 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: General Vision (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.256896634530023" CI_START="1.5431033654699764" EFFECT_SIZE="9.899999999999999" ESTIMABLE="YES" MEAN_1="13.6" MEAN_2="3.7" MODIFIED="2008-06-12 15:24:17 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="16.5" SD_2="13.5" SE="4.263801121065568" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2008-06-16 16:46:14 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Ocular Pain (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.305561687059724" CI_START="-0.3055616870597242" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="-2.0" MODIFIED="2008-06-12 15:25:47 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SD_1="5.5" SD_2="8.0" SE="1.9416487838947598" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2008-06-16 16:46:23 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Near Activity (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.99221059972908" CI_START="-4.592210599729082" EFFECT_SIZE="10.2" ESTIMABLE="YES" MEAN_1="15.5" MEAN_2="5.3" MODIFIED="2008-06-12 15:28:45 +0100" MODIFIED_BY="[Empty name]" ORDER="13" SD_1="32.0" SD_2="20.0" SE="7.547184905645283" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.12" MODIFIED="2008-06-16 16:46:28 +0100" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Social Functioning (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="18.56675867718325" CI_START="-3.1667586771832488" EFFECT_SIZE="7.7" ESTIMABLE="YES" MEAN_1="7.0" MEAN_2="-0.7" MODIFIED="2008-06-12 15:38:20 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="21.5" SD_2="17.5" SE="5.544366510251645" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2008-06-16 16:46:38 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Mental Health (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="24.14383846430117" CI_START="1.0561615356988288" EFFECT_SIZE="12.6" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="4.4" MODIFIED="2008-06-12 15:46:29 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SD_1="22.5" SD_2="19.0" SE="5.8898217290508885" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2008-06-16 16:46:43 +0100" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Role Difficulties (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.994269281007295" CI_START="-6.394269281007296" EFFECT_SIZE="5.3" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="-2.0" MODIFIED="2008-06-12 15:47:18 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SD_1="23.0" SD_2="19.0" SE="5.966573556070519" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.15" MODIFIED="2008-06-16 16:46:50 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Colour Vision (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.071625709791824" CI_START="-0.07162570979182448" EFFECT_SIZE="8.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="-2.0" MODIFIED="2008-06-12 15:47:52 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SD_1="18.0" SD_2="10.0" SE="4.1182520563948" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2008-06-16 16:46:56 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>NEI-VFQ subscale: Peripheral Vision (mean change at 12 months)</NAME>
<GROUP_LABEL_1>Translocation</GROUP_LABEL_1>
<GROUP_LABEL_2>Photodynamic therapy</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PDT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours translocation</GRAPH_LABEL_2>
<CONT_DATA CI_END="25.656420004218468" CI_START="-5.656420004218468" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="12.0" MEAN_2="2.0" MODIFIED="2008-06-12 15:48:43 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SD_1="33.0" SD_2="22.5" SE="7.988116173416609" STUDY_ID="STD-Gelisken-2007" TOTAL_1="25" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-06-13 09:51:55 +0100" MODIFIED_BY="[Empty name]"/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-08-08 12:41:00 +0100" MODIFIED_BY="Anupa Shah">
<APPENDIX ID="APP-01" MODIFIED="2008-08-07 10:18:43 +0100" MODIFIED_BY=" Iris Gordon" NO="1">
<TITLE MODIFIED="2008-08-07 10:18:01 +0100" MODIFIED_BY=" Iris Gordon">CENTRAL search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-07 10:18:43 +0100" MODIFIED_BY=" Iris Gordon">
<P>#1 MeSH descriptor Macular Degeneration<BR/>#2 MeSH descriptor Retinal Degeneration<BR/>#3 MeSH descriptor Retinal Neovascularization<BR/>#4 MeSH descriptor Choroidal Neovascularization<BR/>#5 MeSH descriptor Macula Lutea<BR/>#6 macula* near lutea*<BR/>#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))<BR/>#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))<BR/>#9 maculopath*<BR/>#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)<BR/>#11 macula* near translocat*<BR/>#12 retinotom*<BR/>#13 (#11 OR #12)<BR/>#14 (#10 AND #13)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-08-07 11:09:25 +0100" MODIFIED_BY=" Iris Gordon" NO="2">
<TITLE MODIFIED="2008-08-07 10:19:03 +0100" MODIFIED_BY=" Iris Gordon">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-07 11:09:25 +0100" MODIFIED_BY=" Iris Gordon">
<P>1. randomized controlled trial.pt.<BR/>2. (randomized or randomised).ab,ti.<BR/>3. placebo.ab,ti.<BR/>4. dt.fs.<BR/>5. randomly.ab,ti.<BR/>6. trial.ab,ti.<BR/>7. groups.ab,ti.<BR/>8. or/1-7<BR/>9. exp animals/<BR/>10. exp humans/<BR/>11. 9 not (9 and 10)<BR/>12. 8 not 11<BR/>13. exp macular degeneration/<BR/>14. exp retinal degeneration/<BR/>15. exp retinal neovascularization/<BR/>16. exp choroidal neovascularization/<BR/>17. exp macula lutea/<BR/>18. maculopath$.tw.<BR/>19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.<BR/>20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.<BR/>21. (macula$ adj2 lutea).tw.<BR/>22. or/13-21<BR/>23. (macula$ adj3 translocat$).tw.<BR/>24. retinotom$.tw.<BR/>25. or/23-24<BR/>26. 22 and 25<BR/>27. 12 and 26</P>
<P>The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (<LINK REF="REF-Glanville-2006" TYPE="REFERENCE">Glanville 2006</LINK>).</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-08-07 10:21:56 +0100" MODIFIED_BY=" Iris Gordon" NO="3">
<TITLE MODIFIED="2008-08-07 10:20:50 +0100" MODIFIED_BY=" Iris Gordon">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-07 10:21:56 +0100" MODIFIED_BY=" Iris Gordon">
<P>1. exp randomized controlled trial/<BR/>2. exp randomization/<BR/>3. exp double blind procedure/<BR/>4. exp single blind procedure/<BR/>5. random$.tw.<BR/>6. or/1-5<BR/>7. (animal or animal experiment).sh.<BR/>8. human.sh.<BR/>9. 7 and 8<BR/>10. 7 not 9<BR/>11. 6 not 10<BR/>12. exp clinical trial/<BR/>13. (clin$ adj3 trial$).tw.<BR/>14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.<BR/>15. exp placebo/<BR/>16. placebo$.tw.<BR/>17. random$.tw.<BR/>18. exp experimental design/<BR/>19. exp crossover procedure/<BR/>20. exp control group/<BR/>21. exp latin square design/<BR/>22. or/12-21<BR/>23. 22 not 10<BR/>24. 23 not 11<BR/>25. exp comparative study/<BR/>26. exp evaluation/<BR/>27. exp prospective study/<BR/>28. (control$ or prospectiv$ or volunteer$).tw.<BR/>29. or/25-28<BR/>30. 29 not 10<BR/>31. 30 not (11 or 23)<BR/>32. 11 or 24 or 31<BR/>33. exp retina macula degeneration/<BR/>34. exp retina degeneration/<BR/>35. exp retina neovascularization/<BR/>36. exp subretinal neovascularization/<BR/>37. maculopath$.tw.<BR/>38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.<BR/>39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.<BR/>40. exp retina macula lutea/<BR/>41. (macula$ adj2 lutea$).tw.<BR/>42. or/33-40<BR/>43. (macula$ adj3 translocat$).tw.<BR/>44. retinotom$.tw.<BR/>45. or/43-44<BR/>46. 42 and 45<BR/>47. 32 and 46</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-08-08 12:41:00 +0100" MODIFIED_BY="Anupa Shah" NO="4">
<TITLE MODIFIED="2008-08-07 10:22:12 +0100" MODIFIED_BY=" Iris Gordon">LILACS search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-08-08 12:41:00 +0100" MODIFIED_BY="Anupa Shah">
<P>macul* or retina* or choroid* and degenerat* or neovascula* and translocat* or retinotom*</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>